CTNM Insider Trading Activity and SEC Form 4 Filings
CTNM insider trading summary
Over the past 12 months, insiders at Contineum Therapeutics, Inc. (CTNM) reported 24 sales worth $1.6M by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.6M.
Latest CTNM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone | CEO and President | Sell | $41K (2,500 @ $16.46) |
| Aug 3, 2026 | Carmine N. Stengone | CEO and President | Sell | $40K (2,500 @ $16.01) |
| Jul 9, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sell | $400 (25 @ $16.00) |
| Jul 8, 2026 | Carmine N. Stengone | CEO and President | Sell | $40K (2,500 @ $16.00) |
| Jul 8, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sell | $16K (1,015 @ $16.00) |
| Jul 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sell | $41K (2,501 @ $16.24) |
| Jul 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sell | $92K (5,852 @ $15.67) |
| Jun 30, 2026 | Carmine N. Stengone | CEO and President | Sell | $160K (10,000 @ $16.01) |
| Jun 30, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sell | $462K (28,826 @ $16.04) |
| Jun 30, 2026 | Tim Watkins | CMO & Head of Development | Sell | $174K (10,833 @ $16.02) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.